Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.

MLA

Friedman, Claire F., et al. “Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.” Cancer Discovery, vol. 12, no. 3, Mar. 2022, pp. 654–69. EBSCOhost, https://doi.org/10.1158/2159-8290.CD-21-0450.

APA

Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., Meric-Bernstam, F., Wang, Y., Levy, J., Grindheim, J., Shames, D. S., Schulze, K., Patel, A., & Swanton, C. (2022). Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery, 12(3), 654–669. https://doi.org/10.1158/2159-8290.CD-21-0450

Chicago

Friedman, Claire F, John D Hainsworth, Razelle Kurzrock, David R Spigel, Howard A Burris, Christopher J Sweeney, Funda Meric-Bernstam, et al. 2022. “Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.” Cancer Discovery 12 (3): 654–69. doi:10.1158/2159-8290.CD-21-0450.